GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)

FairStock Score: 74/100 — STEADY

Key Financials

Strengths

• Generates $3.3 billion in annual free cash flow (2.9% yield on market cap)
• High return on equity of 43.3% demonstrating efficient capital deployment
• Attractive 3.2% dividend yield providing steady income returns
• FairStock composite score of 75/100 places it in the top tier across value, quality, and momentum factors
• Established organization with 66,841 employees providing operational scale

Concerns

• Trades significantly above Graham Number ($19) with negative 202% margin of safety—limited downside protection

AI Analysis

GSK plc American Depositary Shares (Each representing two Ordinary Shares) is a large-cap healthcare company valued at $112.7 billion. The business generates $32.7 billion in annual revenue with a 1.9% net margin and $3.3 billion in free cash flow. From a quality standpoint, GSK shows Altman Z-Score of 1.9 in the grey zone and extraordinary 43% return on equity. On valuation, the stock is attractively valued at 14.8x earnings, with trades far above its Graham Number ($19) with no margin of safety. Growth dynamics show revenue growing at 6.2% and profit growth of 53.6%. The 3.2% dividend yield adds an income component for patient holders. Our composite FairStock Score of 75/100 reflects strong fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

The market underappreciates GSK's consistent 43% ROE at just 15x earnings—a re-rating toward sector peers could unlock 30-50% upside. With $3.3 billion in annual free cash flow (2.9% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer